Your AI-Trained Oncology Knowledge Connection!

Rafael Madero-Marroquin, MD

home / authors / rafael-madero-marroquin-md

Articles

COMMANDS and ELEMENT-MDS Trials: Long-Term Analysis, Survival, Duration of Response, and Hemoglobin Levels

Thomas W. LeBlanc, MD, MA;Guru Subramanian Guru Murthy, MD, MS; Raji Shameem, MD;Daniel DeAngelo, MD, PhD;Rafael Madero-Marroquin, MD;Mikkael A. Sekeres, MD, MS

June 24th 2025

Panelists discuss long-term results from a phase 3 trial comparing luspatercept and epoetin alfa in lower-risk MDS, highlighting luspatercept’s superior efficacy in achieving sustained transfusion independence and the need for further research on earlier intervention strategies.

Early vs Late Onset of ESA in LR-MDS: Results From Phase 3 EPO-PRETAR Trial

Thomas W. LeBlanc, MD, MA;Guru Subramanian Guru Murthy, MD, MS; Raji Shameem, MD;Daniel DeAngelo, MD, PhD;Rafael Madero-Marroquin, MD;Mikkael A. Sekeres, MD, MS

June 24th 2025

Panelists discuss the results of the phase 3 EPO-PRETAR trial in a dynamic, debate-style forum on lower-risk myelodysplastic syndromes, weighing the benefits of early vs late erythropoiesis-stimulating agent initiation while highlighting the need for more patient-centered outcome measures.